benazepril Side Effects
Also known as: Lotensin
Analysis of 7,061 adverse event reports submitted to the FDA from 1998 to 2025.
Total Reports
7,061
Death-Related
572
8.1% of reports
Hospitalizations
2,464
34.9% of reports
Top Indication
Hypertension
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 572 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 153 |
| COMPLETED SUICIDE | 81 |
| MYOCARDIAL INFARCTION | 63 |
| RENAL FAILURE | 63 |
| PAIN | 55 |
| ANXIETY | 50 |
| CARDIAC ARREST | 48 |
| CARDIAC FAILURE CONGESTIVE | 48 |
| RESPIRATORY FAILURE | 44 |
| CEREBROVASCULAR ACCIDENT | 43 |
| INJURY | 42 |
| TOXICITY TO VARIOUS AGENTS | 42 |
| CARDIO-RESPIRATORY ARREST | 40 |
| DYSPNOEA | 39 |
| HYPOTENSION | 39 |
| NAUSEA | 35 |
| EMOTIONAL DISTRESS | 31 |
| FATIGUE | 30 |
| DIARRHOEA | 28 |
| MULTI-ORGAN FAILURE | 28 |
Reactions in Hospitalization Reports
Top reactions in 2,464 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| MYOCARDIAL INFARCTION | 264 |
| CARDIAC FAILURE CONGESTIVE | 207 |
| DYSPNOEA | 203 |
| CEREBROVASCULAR ACCIDENT | 196 |
| HYPERTENSION | 175 |
| CHEST PAIN | 172 |
| NAUSEA | 171 |
| PAIN | 156 |
| CORONARY ARTERY DISEASE | 153 |
| DIARRHOEA | 148 |
| ASTHENIA | 146 |
| FATIGUE | 141 |
| DIZZINESS | 137 |
| PNEUMONIA | 136 |
| FALL | 135 |
| VOMITING | 131 |
| RENAL FAILURE | 127 |
| ATRIAL FIBRILLATION | 119 |
| OEDEMA PERIPHERAL | 111 |
| HEADACHE | 107 |
Nearby — Related Medications
What the FAERS Data Reveals About benazepril Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 7,061 voluntary reports linked to benazepril and its brand equivalents (Lotensin), spanning 1998 through 2025. Of those, 572 (8.1%) listed death as an outcome and 2,464 (34.9%) involved hospitalization. The most common indication reported alongside adverse events was Hypertension.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 55% were female and 45% male; age distribution skews toward 45-64, with 1,862 reports in that bracket. The single most reported reaction is nausea with 439 submissions, followed by fatigue and drug ineffective.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.